State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau , Macao 999078, China.
College of Chinese Medicines, Guangzhou University of Chinese Medicine , Guangzhou 510006, China.
Mol Pharm. 2017 Nov 6;14(11):3644-3659. doi: 10.1021/acs.molpharmaceut.7b00404. Epub 2017 Oct 10.
Although tumor-targeting nanovehicles for hepatocellular carcinoma (HCC) chemotherapy have attracted great research and clinic interest, the poor cancer penetration, inefficient cellular uptake, and slow intracellular drug release greatly compromise their therapeutic outcomes. In this work, a multifunctional mixed micellar system, consisting of glycyrrhetinic acid (GA) for specific liver-targeting, trans-activator of transcription (TAT) peptide for potent cell penetration, and pH-sensitive poly(β-amino ester) polymers for acidic-triggered drug release, was developed to provide HCC-targeting delivery and pH-triggered release of doxorubicin (DOX). These micelles were hypothesized to efficaciously accumulate in HCC site by the guide of GA ligands, enter into cancer cells facilitated by the activated TAT peptide on the micellar surface, and finally rapidly release DOX in cytoplasm. To demonstrate this design, DOX was initially loaded in micelles modified with both GA and TAT (DOX/GA@TAT-M) with high drug loading efficiency and pH-sensitive drug release profiles. The HCC-targeting cellular uptake and synergetic anticancer efficacy were tested, indicating DOX/GA@TAT-M could be specifically and effectively internalized into HCC cells by the effect of GA targeting and TAT penetrating with enhanced cytotoxicity. In addition, the prolonged circulation time and enhanced accumulation in tumor facilitated its potent tumor growth inhibition activity in vivo. These results demonstrated that the cleavable multifunctional mixed micelles with tumor targeting, controlled TAT peptide activation, and sequential pH-sensitive drug release could be an efficient strategy for HCC treatment.
尽管针对肝细胞癌 (HCC) 的肿瘤靶向纳米载体引起了广泛的研究和临床关注,但较差的肿瘤穿透性、低效的细胞摄取率和缓慢的细胞内药物释放极大地限制了其治疗效果。在这项工作中,开发了一种多功能混合胶束系统,由用于特异性肝靶向的甘草次酸 (GA)、用于有效细胞穿透的转录激活因子 (TAT) 肽和用于酸性触发药物释放的 pH 敏感的聚 (β-氨基酸酯) 聚合物组成,以提供 HCC 靶向递药和 pH 触发的阿霉素 (DOX) 释放。这些胶束被假设通过 GA 配体的引导有效地在 HCC 部位积累,通过胶束表面上活化的 TAT 肽促进进入癌细胞,并最终在细胞质中快速释放 DOX。为了验证这一设计,首先将 DOX 装载在同时修饰有 GA 和 TAT 的胶束 (DOX/GA@TAT-M) 中,具有较高的载药效率和 pH 敏感的药物释放特性。测试了 HCC 靶向的细胞摄取和协同抗癌功效,表明 DOX/GA@TAT-M 可以通过 GA 靶向和 TAT 穿透的协同作用,被特异性和有效地内化到 HCC 细胞中,从而具有增强的细胞毒性。此外,延长的循环时间和增强的肿瘤积累促进了其在体内的强大肿瘤生长抑制活性。这些结果表明,具有肿瘤靶向、控制 TAT 肽激活和顺序 pH 敏感药物释放的可裂解多功能混合胶束可以成为治疗 HCC 的有效策略。